Log reduction of multidrug-resistant Gram-negative bacteria by the neutrophil-derived recombinant...

Area of Science:

• Microbiology
• Infectious Diseases
• Biochemistry

Background:

• Multidrug-resistant (MDR) Gram-negative bacterial infections pose a significant global health threat.
• Limited therapeutic options are available for treating these infections.
• The bactericidal/permeability-increasing protein (BPI) is a neutrophil-derived protein that binds lipopolysaccharide (LPS) on Gram-negative bacteria.

Purpose of the Study:

• To evaluate the efficacy of a recombinant fragment of BPI, rBPI-21, against MDR Gram-negative bacteria.
• To assess the potential of rBPI-21 as a therapeutic agent for MDR Gram-negative infections.

Main Methods:

• In vitro incubation of MDR Pseudomonas and Acinetobacter with varying doses of rBPI-21.
• Quantification of bacterial reduction after 1-hour incubation.
• Utilized clinically achievable doses of rBPI-21.

Main Results:

• A dose-dependent reduction of 1-2 log in MDR Pseudomonas and Acinetobacter was observed.
• The observed bacterial reduction occurred within 1 hour of incubation.
• rBPI-21 demonstrated efficacy at clinically relevant concentrations.

Conclusions:

• rBPI-21 exhibits potent bactericidal activity against key MDR Gram-negative pathogens.
• The established safety profile of rBPI-21 from previous trials supports its further investigation.
• rBPI-21 represents a promising candidate for combating the growing threat of MDR Gram-negative bacterial infections.